NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The firm is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The firm has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The firm is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic.
Follow-Up Questions
What is the price performance of NRXP stock?
The current price of NRXP is $2.75, it has decreased 0% in the last trading day.
What are the primary business themes or industries for NRX Pharmaceuticals Inc?
NRX Pharmaceuticals Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is NRX Pharmaceuticals Inc market cap?
NRX Pharmaceuticals Inc's current market cap is $65.4M
Is NRX Pharmaceuticals Inc a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for NRX Pharmaceuticals Inc, including 3 strong buy, 6 buy, 1 hold, 0 sell, and 3 strong sell
